Clinical Trial Update: A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) [Phase 2]

View source ↗

Summary

Phase 2 trial START SYNERGY is evaluating multiple doses of ELV001 to treat active rheumatoid arthritis in patients with inadequate response to methotrexate and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ELV001

Snippet

Sponsor: Elevara Medicines Limited | Conditions: Active Rheumatoid Arthritis | Phase 2 | Status: RECRUITING